July 15, 2025

Genetic Markers Don’t Guide RA Drug Choice

A large UK study found no significant difference in treatment effectiveness between abatacept and adalimumab for rheumatoid arthritis, regardless of patients’ HLA-DRB1 genetic profiles.

Conexiant

July 15, 2025

Methotrexate Shows No Knee OA Symptom Benefit, Study Finds

A 52-week randomized clinical trial found no significant difference between methotrexate and placebo in reducing pain or effusion-synovitis in patients with inflammatory knee osteoarthritis.

Conexiant

July 14, 2025

Skin Autoimmune Disorders Tied to Longer Cancer Survival

A large nationwide study in Taiwan found that patients with autoimmune skin diseases had lower all-cause and cancer-specific mortality following cancer treatment compared with those without these conditions.

Conexiant

July 09, 2025

Recombinant Zoster Vaccine Linked to New-Onset Lupus

Researchers report the first documented case of systemic lupus erythematosus following Shingrix vaccination.

Conexiant

July 09, 2025

Upadacitinib Cuts Flares, Steroids in GCA Trial

A new phase 3 study found that daily oral upadacitinib 15 mg, combined with a shorter 26-week steroid taper, improved sustained remission rates and reduced steroid use in patients with giant-cell arteritis.

Conexiant

June 30, 2025

Can Typos Change a Diagnosis?

Large language models used in clinical decision-making may offer different treatment recommendations depending on how a patient writes their message—even when the medical facts remain unchanged.

Conexiant

June 27, 2025

Gout and Ultrasound Predict Carotid Risk

Ultrasound features and gout flares help identify patients at risk for carotid plaque vulnerability, a key factor in stroke risk.

Conexiant

June 26, 2025

First Targeted Therapy Approved for BP

The FDA has approved dupilumab as the first targeted treatment for adults with bullous pemphigoid, showing improved remission rates and reduced corticosteroid use.

Conexiant

June 26, 2025

MRI Finds Hidden Arthritis After Cancer Therapy

A new imaging study found that patients who develop joint pain after cancer immunotherapy often show significant inflammation and joint damage on MRI—even when physical signs of arthritis are absent.

Conexiant